Cue Biopharma, Inc. (CUE)
About Cue Biopharma, Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $27.5M
- Net income
- -$26.6M
- Total assets
- $42.2M
- Market cap
- $134.9M
- Operating margin
- -96.7%
- Net margin
- -96.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $27.5M
- Operating expenses
- $54.0M
- Operating income
- -$26.6M
- Income tax
- $500.0K
- Net income
- -$26.6M
- EPS (basic)
- $-0.28
- EPS (diluted)
- $-0.28
Balance sheet
- Total assets
- $42.2M
- Current assets
- $37.0M
- Total liabilities
- $15.8M
- Current liabilities
- $13.5M
- Shareholders’ equity
- $26.4M
Cash flow
- Operating cash flow
- -$21.7M
- Investing cash flow
- $75.0K
- Financing cash flow
- $26.3M
- Net cash flow
- $4.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $134.9M
- EPS (diluted)
- $-0.28
- Shares outstanding
- 5.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 2, 2018
Cue Biopharma, Inc. (CUE) Stock Price
- Reported a net loss of $26.6M in FY2025.
- Revenue grew 84% from FY2021 to FY2025.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cue Biopharma, Inc..
Write a review
News about Cue Biopharma, Inc.
News & sentiment via Polygon.io
Cue Biopharma, Inc.: frequently asked questions
Is Cue Biopharma, Inc. an American company?
Cue Biopharma, Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Cue Biopharma, Inc. headquartered?
Cue Biopharma, Inc. is headquartered in Boston, Massachusetts, United States.
Is Cue Biopharma, Inc. publicly traded?
Yes — Cue Biopharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol CUE on the NASDAQ.
What does Cue Biopharma, Inc. do?
Cue Biopharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
